UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                February 19, 2004


                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

   DELAWARE               000-29089                       06-1562417
(State or other    (Commission file number) (I.R.S. Employer Identification No.)
 jurisdiction of
 incorporation of
 organization)

                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)









Item 7.   Financial Statements, Pro Forma Financial Statements and Exhibits.

(c) Exhibits:

99.1      Press Release dated February 19, 2004

Item 12.  Disclosure of Results of Operations and Financial Condition

          On February 19, 2004,  Antigenics Inc. announced its financial results
          for the quarter and year ended December 31, 2003. The full text of the
          press release issued in connection  with the  announcement is attached
          as Exhibit 99.1 to this current report on Form 8-K.

          The  information  in this report on Form 8-K and the Exhibit  attached
          hereto is being furnished pursuant to Item 12 of Form 8-K,  Disclosure
          of Results of Operations  and  Financial  Condition.  The  information
          shall  not  be  deemed  "filed"  for  purposes  of  Section  18 of the
          Securities  Exchange  Act of 1934 (the  "Exchange  Act") or  otherwise
          subject to the  liabilities  of that  section,  nor shall it be deemed
          incorporated  by reference in any filing under the  Securities  Act of
          1933 or the Exchange  Act,  except as expressly  set forth by specific
          reference in such a filing.












                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                               ANTIGENICS INC.


Date: February 19, 2004                                 By:  /s/ Garo H. Armen
                                                           --------------------
                                                           Garo H. Armen, Ph.D.
                                           Chairman and Chief Executive Officer













                                  EXHIBIT INDEX


The following designated exhibits are filed herewith:

Exhibits:

99.1           Press Release dated February 19, 2004